January 1, 1997Journal of Hypertension

Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

JCJean‐Paul ClozelInserm EEEric A. ErtelIdorsia (Switzerland)SESylvie I. ErtelUniversity Hospital of Geneva

Discussion

Member takes

Implication

Mibefradil's profile may support trials in hypertension or HF; leaves open clinical efficacy and safety.

Structured PICO

Intervention

Mibefradil (Ro 40-5967)

Mibefradil's unique pharmacological profile as a selective T-type calcium channel blocker suggests potential therapeutic utility in hypertension, angina, and congestive heart failure.

Cite This Study

Clozel et al. (1997) studied this question.

synapsesocial.com/papers/6a79660277336a1bae0248aa https://doi.org/10.1097/00004872-199715055-00004

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider